Treatment of Anxiety Disorders for Children and Adolescents in Regular Outpatient Clinics

Anxiety Disorders Clinical Trial

— TADCAROC  

Official title:

Treatment of Anxiety Disorders for Children and Adolescents in Regular Outpatient Clinics (TADCAROC)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02218996
• Other study ID #: ID416
• Status: Active, not recruiting
• Start date: August 2014
• Est. completion date: December 31, 2029

Study information

• Verified date: November 2022
• Source: Helse Stavanger HF
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to examine the content of the treatment being delivered for anxiety disorders for children and adolescents in the regular outpatient clinics in western Norway. The study will also collect data before and after treatment to evaluate the result of the treatment. Furthermore, as part of the study we aim to collect normative data on two questionnaires used to identify anxiety symptoms and the extent to which anxiety interfere with daily functioning. We also aim to develop a quality indicator for anxiety treatment that can be used to monitor treatment in the regular outpatient service, based on the results of the current study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 260
• Est. completion date: December 31, 2029
• Est. primary completion date: December 31, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 7 Years to 17 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of an anxiety disorder (including PTSD and OCD) based on the diagnostic interview ADIS (ADIS-C/P; Silverman & Albano, 1996).

• The anxiety disorder is the patients primary diagnosis.

• Informed concent is given.

Exclusion Criteria:

• The patient is in need for other primary treatment intervention (e.g., psychosis, suicidality risk)

Related Conditions & MeSH terms

• Anxiety Disorders

Intervention

Other:
• Psychosocial treatment
Regular psychosocial treatment in clinical outpatient service.

Locations

Country	Name	City	State
Norway	BUPA Helse Stavanger	Stavanger	Rogaland

Sponsors (2)

Lead Sponsor	Collaborator
Helse Stavanger HF	Helse Vest

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Anxiety Disorder Interview Schedule for Diagnostic and Statistical Manual (DSM-IV), child and parent versions (ADIS- C/P; Silverman & Albano, 1996).	Diagnostic interview for anxiety disorders and other comorbid disorders. For the 10-year follow-up we anticipate to use another version of the diagnostic interview schedule based on revised diagnostic criteria for anxiety disorders.	The primary outcome measure will be administered pre-treatment, post treatment (an expected average of 20 weeks) and at ten year follow-up.
Secondary	Children's Anxiety Life Interference Scale (CALIS; Lyneham et al., 2013)		This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks).
Secondary	The Screen for Child Anxiety Related Emotional Disorders (SCARED; Birmaher et al., 1999).		This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks).
Secondary	Spence Children's Anxiety Scale (SCAS; Spence, 1998)		This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks).
Secondary	The Strengths and Difficulties Questionnaire (SDQ; Goodman, 1997)		This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks)
Secondary	Short Mood & Feeling Questionaire (SMFQ; Angold et al., 1995).		This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks)
Secondary	Clinical Global Impressions (CGI; Guy, 1976).		The outcome measure will be administered pre-treatment, post treatment (an expected average of 20 weeks) and at ten year follow-up.